Incyte (INCY) Interest Coverage Ratio (2010 - 2026)
Incyte's (INCY) quarterly Interest Coverage Ratio came in at 110.78 in Q2 2026, up 19.07% YoY from 93.04 in Q2 2025, and up 135.45% on a QoQ basis from 47.05 in Q1 2026.
Incyte (INCY) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Interest Coverage Ratio data on file, last reported at 110.78 in Q2 2026.
- Quarterly Interest Coverage Ratio rose 19.07% year-over-year to 110.78 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1125.56 (down 2145.48% YoY) and the FY2025 annual result came in at 67.63, up 235699.99% from the prior year.
- Interest Coverage Ratio rose to 110.78 in Q2 2026, from 47.05 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 749.19 in Q3 2025 to a low of 91.95 in Q2 2024.
- A 5-year average of 73.29 and a median of 39.16 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio slumped 289.8% — and 2025, when it surged 2566.78%.
- Tracing INCY's Interest Coverage Ratio over 5 years: stood at 105.09 in 2022, then slumped by 114.79% to 15.54 in 2023, then surged by 504.15% to 62.82 in 2024, then sank by 135.95% to 22.58 in 2025, then jumped by 590.53% to 110.78 in 2026.
- The last three Interest Coverage Ratio figures came in at 110.78 (Q2 2026), 47.05 (Q1 2026), and 22.58 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 110.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.78 |
| Mar 31, 2026 | 47.05 |
| Dec 31, 2025 | -22.58 |
| Sep 30, 2025 | 749.19 |
| Jun 30, 2025 | 93.04 |
| Mar 31, 2025 | 35.37 |
| Dec 31, 2024 | 62.82 |
| Sep 30, 2024 | 28.09 |
| Jun 30, 2024 | -91.95 |
| Mar 31, 2024 | 17.02 |
| Dec 31, 2023 | -15.54 |
| Sep 30, 2023 | 42.94 |
| Jun 30, 2023 | 48.45 |
| Mar 31, 2023 | 4.42 |
| Dec 31, 2022 | 105.09 |
| Sep 30, 2022 | 27.13 |
| Jun 30, 2022 | 54.13 |
| Mar 31, 2022 | 23.78 |
| Dec 31, 2021 | 147.25 |
| Sep 30, 2021 | 3.64 |